Effect of anlotinib combined with ticeorgio for recurrent nasopharyngeal carcinoma: a case report

For patients with locally unresectable recurrent nasopharyngeal carcinoma who relapsed after 2 years of radiotherapy, re-radiotherapy is also the preferred treatment. However, for within years, use would be greatly limited by its adverse effects. Consequently, finding a new strategy to prolong time very necessary reduce related side effects and improve curative effect. Anlotinib an orally available small molecule multi-target tyrosine kinase inhibitor that primarily inhibits VEGFR2/3, FGFR1–4, PDGFR α/β, c-Kit, Ret. whether can treated anlotinib combined ticeorgio (also called S-1) remains unknown. Herein, we report patient local recurrence radical radiotherapy benefited from combination treatment ticeorgio.